Can Animal Models of Disease Reliably Inform Human Studies
A recent meta-analysis of randomized controlled trials (RCTs), including AMPLITUDE-O, examining six GLP-1 receptor agonists (lixisenatide, liraglutide, subcutaneous semaglutide, exenatide, dulaglutide, and efpeglenatide) reported a 21% reduction in a composite kidney outcome (macroalbuminuria, doubling of serum creatinine or 40% eGFR decline, RRT, or death from kidney disease), corresponding to a number needed to treat of 47 [73]
10.1124/jpet.111.181297 J
Our pilot study suggests that oral administration of glutathione supports hepatic metabolism and improves NAFLD
Enhances learning and memory
If you report fatigue, your provider may choose methylcobalamin or L-carnitine